Pfizer Competitors or Alternatives

Pfizer's top competitors include Lilly, AstraZeneca and Novartis.

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Pfizer's company profile

Albert Bourla

Chairman & CEO

60/100
83,000
$1B
$62.6B
1
Pfizer's Competitor - Lilly logo

David A Ricks

Chairman & CEO

82/100
39,000
$6.7B
$65.2B
2
Pfizer's Competitor - AstraZeneca logo

Pascal Soriot

CEO

65/100
94,300
$100M
$57.2B
3
Pfizer's Competitor - Novartis logo

Vasant Narasimhan

CEO

88/100
75,883
$11B
$54.1B
4
Pfizer's Competitor - Bristol-Myers Squibb logo

Christopher Boerner

CEO

49/100
34,300
$23.5B
$48.2B
5
Pfizer's Competitor - Amgen logo

Robert A. Bradway

Chairman & CEO

63/100
25,200
$4.1B
$36.8B

Pfizer VS Lilly

Eli Lilly CEO David A. Ricks has an approval rating of 77 out of 100 compared to Pfizer CEO Albert Bourla who has an approval rating of 71 out of 100. David A. Ricks has an approval rating that is higher than the approval rating of Albert Bourla. With an employee count of 39,000 people, Eli Lilly is outnumbered by Pfizer which has an employee count totaling 83,000 people. Eli Lilly generates less annual revenue than Pfizer. Pfizer’s annual revenue is $93B while Eli Lilly generates a total annual revenue of $27.7B. Pfizer has 44 subsidiaries with its latest acquisition of Lucira Health, Inc. occurring in Apr 2023. Eli Lilly has 27 subsidiaries with its latest acquisition of Akouos, Inc. occurring in Oct 2022. In Feb 2022, Cynthia Cardona joined Eli Lilly as President of The Eli Lilly and Company Foundation, Inc. and Senior Director.

Pfizer VS AstraZeneca

AstraZeneca CEO Pascal Soriot has an approval rating of 68 out of 100 compared to Pfizer CEO Albert Bourla who has an approval rating of 71 out of 100. Pascal Soriot has an approval rating that is slightly lower than the approval rating of Albert Bourla. With an employee count of 83,500 people, AstraZeneca outnumbers Pfizer which has an employee count totaling 83,000 people. AstraZeneca generates less annual revenue than Pfizer. Pfizer’s annual revenue is $93B while AstraZeneca generates a total annual revenue of $44.4B. Pfizer has 44 subsidiaries with its latest acquisition of Lucira Health, Inc. occurring in Apr 2023. AstraZeneca has 18 subsidiaries with its latest acquisition of CinCor Pharma, Inc. occurring in Jan 2023. Alastair Smith joined AstraZeneca as Director Global Procurement - Insight and Technology in Dec 2022.

Pfizer VS Novartis

Novartis CEO Vasant Narasimhan has an approval rating of 56 out of 100 compared to Pfizer CEO Albert Bourla who has an approval rating of 71 out of 100. Vasant Narasimhan has an approval rating that is significantly lower than the approval rating of Albert Bourla. With an employee count of 102,00 people, Novartis outnumbers Pfizer which has an employee count totaling 83,000 people. Novartis generates less annual revenue than Pfizer. Pfizer’s annual revenue is $93B while Novartis generates a total annual revenue of $50.5B. Pfizer has 44 subsidiaries with its latest acquisition of Lucira Health, Inc. occurring in Apr 2023. Novartis has 25 subsidiaries with its latest acquisition of Kedalion Therapeutics, Inc. occurring in Jun 2022. Novartis and a23andMe announced a collaboration with to increase awareness for Lipoprotein(a) (Lp(a)).

Frequently Asked Questions about Pfizer

  1. Who are Pfizer's top competitors?

    Pfizer's top 3 competitors are Lilly, AstraZeneca, Novartis.
  2. Who is similar to Pfizer?

    Lilly is the most similar to Pfizer. AstraZeneca and Novartis are also similar to Pfizer.
  1. Are Pfizer and Lilly competitors?

    Yes, Lilly is one of Pfizer’s top competitors.